General Information


We are a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders. We were founded to capture the opportunities presented by the confluence of two major developments––the emergence of an attractive and growing biologics market in China, and the revolutionary scientific breakthroughs in cancer and autoimmune disease medicines.

Employees: 185
Founded: 2007
Contact Information
Address Suite 802, West Tower, OmniVision, 88 Shangke Road, Pudong District, Shanghai, People’s Republic of China
Phone Number +86 21-6057-8000
Web Address http://www.i-mabbiopharma.com/en/
View Prospectus: I-MAB
Financial Information
Market Cap $778.3mil
Revenues $6.7 mil (last 12 months)
Net Income $-146.8 mil (last 12 months)
IPO Profile
Symbol IMAB
Exchange NASDAQ
Shares (millions): 7.4
Price range $14.00 - $14.00
Est. $ Volume $103.7 mil
Manager / Joint Managers Jefferies/ CICC
CO-Managers China Renaissance/ Huatai Securities
Expected To Trade: 1/17/2020
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change